PMA device
LimFlow System, LimFlow Crossing Stent Graft, LimFlow Extension Stent Graft
LimFlow, Inc. · Stent Graft, Infrapopliteal, Venous Arterialization (QWN, Class III) · First FDA decision Sep 11, 2023, newest Jul 11, 2024Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
Breakthrough-designated
Device trials
5
Naming "LimFlow"
MAUDE reports
13
Brand "LimFlow", since 2015
PubMed studies
21
Mentioning "LimFlow"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing LimFlow System, LimFlow Crossing Stent Graft, LimFlow Extension Stent Graft
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
P220025-S002 · Decided Jul 11, 2024 · 115 days after receipt · Normal 180 Day Track
Device type: Stent graft, infrapopliteal, venous arterialization (QWN) · Cardiology
- LimFlow SystemPMA supplement
P220025-S001 · Decided Oct 12, 2023 · 27 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent graft, infrapopliteal, venous arterialization (QWN) · Cardiology
- LimFlow SystemBreakthroughPMA
P220025 · Decided Sep 11, 2023 · 315 days after receipt
Device type: Stent graft, infrapopliteal, venous arterialization (QWN) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Venous Angioplasty with or without Stent Placement for the Treatment of Chronic Cerebrospinal Venous InsufficiencyLocal determinationIn effectL35028Wellpoint FederalUpdated Jul 14, 2026
- Endovenous StentingLocal determinationIn effectL38231First Coast Service Options, Inc.Updated Nov 13, 2020
- Endovenous StentingLocal determinationIn effectL37893Novitas Solutions, Inc.Updated Nov 6, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "LimFlow", any status and sponsor, newest update first.
LimFlow, Inc.Not on our public-company list
NCT05313165 · 100 participants (planned) · Start Dec 22, 2022 · Primary completion May 1, 2027
Device: LimFlow Stent Graft System · For: Critical Limb Ischemia; Chronic Limb-Threatening Ischemia; Peripheral Arterial Disease
Sites: La Jolla, California; Palo Alto, California; San Francisco, California · 30 sites in all
LimFlow SANot on our public-company list
NCT03807661 · 28 participants · Start Dec 11, 2019 · Primary completion Oct 9, 2023
Device: LimFlow System · For: Critical Limb Ischemia
Sites: Bristol, United Kingdom; Leicester, United Kingdom; Liverpool, United Kingdom · 6 sites in all
- PROMISE InternationalCompleted
LimFlow SANot on our public-company list
NCT03321552 · 34 participants · Start Dec 15, 2017 · Primary completion Jan 23, 2025
Device: LimFlow System · For: Critical Limb Ischemia
Sites: Graz, Austria; Heidelberg, Germany; Karlsbad, Germany · 12 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "LimFlow", and for the whole product code for context.
This brand
13 reports: 10 malfunction, 3 injury, 0 death
Whole product code QWN
8 reports: 5 malfunction, 3 injury, 0 death
Newest reports for this brand
3023527320-2026-00004 · Received Oct 8, 2026 · Event dated Sep 4, 2026
Device type: Stent Graft, Infrapopliteal, Venous Arterialization (QWN)
Device problem as coded: Fracture
Patient problem as coded: Thrombosis/Thrombus
- LimFlow Extension Stent Graft, 5.5mm x 150mmMalfunction
3023527320-2026-00003 · Received Sep 30, 2026 · Event dated Sep 2, 2026
Device type: Stent Graft, Infrapopliteal, Venous Arterialization (QWN)
Device problem as coded: Dent in Material
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- LimFlow Extension Stent Graft, 5.5mm x 200mmMalfunction
3023527320-2026-00002 · Received Sep 11, 2026 · Event dated Aug 14, 2026
Device type: Stent Graft, Infrapopliteal, Venous Arterialization (QWN)
Device problem as coded: Physical Resistance/Sticking
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "LimFlow"[tiab]. The summary above synthesizes these.
- Improving Bioactive Characteristics of Small Diameter Polytetrafluoroethylene Stent Grafts by Electrospinning: A Comparative Hemocompatibility Study.
Avci-Adali M, Grözinger G, Cabane V, et al. · Bioengineering (Basel) · 2023
- Transcatheter Arterialization of Deep Veins in Chronic Limb-Threatening Ischemia.
Shishehbor MH, Powell RJ, Montero-Baker MF, et al. · N Engl J Med · 2023Multicenter Study
- Updates on the Utilization of Percutaneous Deep Vein Arterialization in End-Stage Peripheral Arterial Disease.
Pai A, Choinski KN, Palvannan P, et al. · Surg Technol Int · 2024
- Novel Therapies for Critical Limb-Threatening Ischemia.
Karimi A, Lauria AL, Aryavand B, et al. · Curr Cardiol Rep · 2022Review
- Off-the-shelf Percutaneous Deep Vein Arterialization (pDVA).
Naga A, Hamo N, Lakin C, et al. · Vasa · 2026Review
- The Feasibility and Applicability of Percutaneous Deep Vein Arterialization in Peripheral Artery Disease.
Choinski KN, Stafford NJ, Rao AG, et al. · Surg Technol Int · 2022
- Durable Long-Term Outcomes After Early Transcatheter Arterialization of the Deep Veins.
Patel A, Shishehbor MH · JACC Case Rep · 2025Case Reports
- 1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies.
Shishehbor MH, Zayed H, Dua A, et al. · JACC Cardiovasc Interv · 2025Multicenter Study, Research Support, Non-U.S. Gov't
- Midterm Outcomes of Percutaneous Deep Venous Arterialization With a Dedicated System for Patients With No-Option Chronic Limb-Threatening Ischemia: The ALPS Multicenter Study.
Schmidt A, Schreve MA, Huizing E, et al. · J Endovasc Ther · 2020Multicenter Study
- PROMISE I: Early feasibility study of the LimFlow System for percutaneous deep vein arterialization in no-option chronic limb-threatening ischemia: 12-month results.
Clair DG, Mustapha JA, Shishehbor MH, et al. · J Vasc Surg · 2021Clinical Trial, Multicenter Study
- Fenestrated Transcatheter Arterialization of the Deep Veins: Protecting the Peroneal While Covering the Tibioperoneal Trunk.
Ingraham BS, Motiei A · JACC Case Rep · 2025Case Reports
- Mid-Term Outcomes of Percutaneous Deep Venous Arterialization Using the LimFlow System.
Morshed AM, Thulasidasan N, Nair H, et al. · J Endovasc Ther · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.